1. Home
  2. SGA vs CSBR Comparison

SGA vs CSBR Comparison

Compare SGA & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saga Communications Inc. (FL)

SGA

Saga Communications Inc. (FL)

HOLD

Current Price

$5.92

Market Cap

56.6M

ML Signal

HOLD

Logo Champions Oncology Inc.

CSBR

Champions Oncology Inc.

N/A

Current Price

$4.59

Market Cap

65.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SGA
CSBR
Founded
1986
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.6M
65.4M
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
SGA
CSBR
Price
$5.92
$4.59
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 16.1K
6.8K
Earning Date
11-12-2026
12-14-2026
Dividend Yield
★ 15.15%
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $124,829,000.00
$2,900,000.00
Revenue This Year
N/A
$9.83
Revenue Next Year
N/A
$8.50
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 5.65
N/A
52 Week Low
$6.55
$4.40
52 Week High
$12.76
$8.31

Technical Indicators

Market Signals
Indicator
SGA
CSBR
Relative Strength Index (RSI) 19.91 28.74
Support Level N/A N/A
Resistance Level $9.41 $6.29
Average True Range (ATR) 0.44 0.12
MACD -0.11 -0.04
Stochastic Oscillator 25.87 0.00

Price Performance

Historical Comparison
SGA
CSBR

About SGA Saga Communications Inc. (FL)

Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.

Share on Social Networks: